# Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

> **NCT03259503** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Hodgkin Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Gemcitabine
- **DRUG:** Melphalan
- **DRUG:** Olaparib
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **OTHER:** Pharmacokinetic Study
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT03259503
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-13
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-11-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259503, "Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03259503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*